Technology ID
TAB-2749
Stable, Early-stage Biomarker for Diagnosis of Bacillus anthracis Infection and Anthrax Vaccine Development
E-Numbers
E-474-2013-0
Lead Inventor
Saile, Elke (CDC)
Co-Inventors
Quinn, Conrad (CDC)
Boons, Geert-Jan (University of Georgia)
Carlson, Russell (University of Georgia)
Applications
Vaccines
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In vivo data available (animal)
Research Products
Research Equipment
Antibodies
Lead IC
CDC
ICs
CDC
This invention comprises monoclonal antibodies, proteins, and related nucleic acid coding sequences that identify all or part of the antigenic anthrose oligosaccharide of Bacillus anthracis, the causative agent of anthrax toxicity in humans. It is imperative to identify virulent B. anthracis with speed and specificity, however there presently is substantial difficulty in early-stage recognition and diagnosis of anthrax inhalation. Improved diagnostic assays that can reliably identify anthrax exposure in its earliest stages and distinguish anthrax from other flu-like illnesses are sorely needed.
CDC and collaborative researchers have developed this technology and confirmed the value of a anthrose biomarker assay as a potentially valuable tool in informing early-stage response decisions following potentially anthrax exposure with in vivo primate data. This invention may be used for development of point-of-care anthrax exposure tests, as well as therapeutics and vaccines directed against B. anthracis.
CDC and collaborative researchers have developed this technology and confirmed the value of a anthrose biomarker assay as a potentially valuable tool in informing early-stage response decisions following potentially anthrax exposure with in vivo primate data. This invention may be used for development of point-of-care anthrax exposure tests, as well as therapeutics and vaccines directed against B. anthracis.
Commercial Applications
- Biodefense, biosecurity
- Point-of-care B. anthracis-exposure diagnostic
- Anthrax vaccine development
- Development of B. anthracis therapeutics
Competitive Advantages
- Valuable tools for screening at-risk individuals following possible anthrax exposure
- May be developed as a rapid, lateral-flow assay for emergency point-of-care diagnosis
- In vivo primate studies validate efficacy as serologic biomarker following aerosolized spore exposure
- Anthrose biomarker assay readout is critically unaffected by ciprofloxacin (anti-anthrax) treatment
Licensing Contact: